HRP20192030T1 - Kristalni oblik bisulfatnog inhibitora jak kinaze i postupak njegovog dobivanja - Google Patents
Kristalni oblik bisulfatnog inhibitora jak kinaze i postupak njegovog dobivanja Download PDFInfo
- Publication number
- HRP20192030T1 HRP20192030T1 HRP20192030TT HRP20192030T HRP20192030T1 HR P20192030 T1 HRP20192030 T1 HR P20192030T1 HR P20192030T T HRP20192030T T HR P20192030TT HR P20192030 T HRP20192030 T HR P20192030T HR P20192030 T1 HRP20192030 T1 HR P20192030T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- root
- formulation
- use according
- radix
- Prior art date
Links
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 19
- 238000009472 formulation Methods 0.000 claims 7
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 229960004676 antithrombotic agent Drugs 0.000 claims 4
- 208000001738 Nervous System Trauma Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 208000029028 brain injury Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 208000028412 nervous system injury Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 241000254032 Acrididae Species 0.000 claims 1
- 241000382455 Angelica sinensis Species 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 206010004542 Bezoar Diseases 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 241000755719 Crinum Species 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 241000545744 Hirudinea Species 0.000 claims 1
- 241000237903 Hirudo Species 0.000 claims 1
- 239000009636 Huang Qi Substances 0.000 claims 1
- 235000005357 Lilium superbum Nutrition 0.000 claims 1
- 241000736199 Paeonia Species 0.000 claims 1
- 235000006484 Paeonia officinalis Nutrition 0.000 claims 1
- 235000003143 Panax notoginseng Nutrition 0.000 claims 1
- 241000180649 Panax notoginseng Species 0.000 claims 1
- 241001555133 Picrodendron baccatum Species 0.000 claims 1
- 241000239226 Scorpiones Species 0.000 claims 1
- 235000012419 Thalia geniculata Nutrition 0.000 claims 1
- 244000081822 Uncaria gambir Species 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- 229940125672 glycoprotein IIb/IIIa inhibitor Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000009112 niuhuang Substances 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000008678 sanqi Substances 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (9)
1. Sastav za korištenje u liječenju moždanog udara, srčanog udara, neurodegenerativne bolesti, ozljede mozga, i ozljede živčanog sustava, obuhvaćajući:
(A) Dang Gui (Radix Angelica sinensis);
(B) barem jedan od sljedećih sastojaka: korijen Radix Astragali (korijen kozlinca ili Huang Qi), korijen Radix et Rhizoma Salviae Miltiorrhizae (korijen crvene kadulje ili Dan Shen), korijen Radix Paeoniae Rubra (korijen crvenog božura ili Chi Shao), podanke Lingusticum Chuanxiong (Chuan Xiong), Radix et Rhizoma Notoginseng (Sanqi), Cortex moutan (božur ili Mudanpi), drvo palisandrovine (Jiang Xiang), osušeno tijelo škorpiona (Quan Xie), korijen Radix Polygalae (Yuan Zhi), podanke močvarnog ljiljana (Shi Changpu), pijavice (Hirudo ili Shuizhi), trčkove (ili Tu Bie Chong), prirodan ili umjetan kravlji bezoar (calculus Bovis artifactus ili Rengong Niuhuang), stabljiku s kukicama biljke gambir (Ramulus uncariae cum uncis ili Gou Teng); i
(C) agens korišten u zapadnjačkoj medicini za liječenje moždanog udara, srčanog udara, neurodegenerativne bolesti, ozljede mozga ili ozljede živčanog sustava, koji je antitrombotski agens.
2. Sastav za korištenje prema zahtjevu 1, naznačen time da, za (B), sastav obuhvaća barem 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 ili 14 od sastojaka.
3. Sastav za korištenje prema zahtjevu 1 ili zahtjevu 2, naznačen time da je bilo koji od (A), (B) i (C) prisutan kao zasebna formulacija.
4. Pribor za korištenje u liječenju moždanog udara, srčanog udara, neurodegenerativne bolesti, ozljede mozga ili ozljede živčanog sustava, pribor obuhvaćajući:
(i) sastav koji se sastoji od (A) i (B) iz zahtjeva 1;
(ii) upute za davanje navedenog sastava pacijentu; i
(iii) agens korišten u zapadnjačkoj medicini koji je antitrombotski agens, za istovremeno, odvojeno ili uzastopno korištenje s navedenim sastavom.
5. Sastav za korištenje prema zahtjevu 1, naznačen time da su (A) i (B) prisutni u jedinstvenoj formulaciji i (C) je zasebna formulacija.
6. Sastav za korištenje prema zahtjevu 5, naznačen time da se formulacija koja obuhvaća (A) i (B) pacijentu daje u isto vrijeme kad i formulacija koja obuhvaća (C).
7. Sastav za korištenje prema zahtjevu 5, naznačen time da se formulacija koja obuhvaća (A) i (B) pacijentu daje u različito vrijeme nego formulacija koja obuhvaća (C).
8. Sastav za korištenje prema bilo kojem od prethodnih zahtjeva, naznačen time da se antitrombotski agens odabire od aspirina, ticlopodina, clopidogrela, PDE III inhibitora, inhibitora ponovne pohrane adenozina, inhibitora glikoproteina IIb/IIIa ili oralno aktivnog RGD mimetskog predlijeka.
9. Sastav za korištenje prema zahtjevu 8, naznačen time da je antitrombotski agens aspirin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410617808 | 2014-11-05 | ||
| PCT/CN2015/091527 WO2016070697A1 (zh) | 2014-11-05 | 2015-10-09 | 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法 |
| EP15857844.3A EP3216790B1 (en) | 2014-11-05 | 2015-10-09 | Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192030T1 true HRP20192030T1 (hr) | 2020-02-07 |
Family
ID=55908546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192030TT HRP20192030T1 (hr) | 2014-11-05 | 2019-11-08 | Kristalni oblik bisulfatnog inhibitora jak kinaze i postupak njegovog dobivanja |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10023577B2 (hr) |
| EP (1) | EP3216790B1 (hr) |
| JP (1) | JP6851572B2 (hr) |
| KR (1) | KR102522895B1 (hr) |
| CN (1) | CN105980390B (hr) |
| AU (1) | AU2015342444B2 (hr) |
| BR (1) | BR112017007953B1 (hr) |
| CA (1) | CA2965716C (hr) |
| CY (1) | CY1122468T1 (hr) |
| DK (1) | DK3216790T3 (hr) |
| ES (1) | ES2754548T3 (hr) |
| HR (1) | HRP20192030T1 (hr) |
| HU (1) | HUE047404T2 (hr) |
| PL (1) | PL3216790T3 (hr) |
| PT (1) | PT3216790T (hr) |
| RS (1) | RS59669B1 (hr) |
| RU (1) | RU2716260C2 (hr) |
| SI (1) | SI3216790T1 (hr) |
| TW (1) | TWI672305B (hr) |
| WO (1) | WO2016070697A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3417861B1 (en) | 2016-02-19 | 2020-09-23 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof |
| TW201827436A (zh) * | 2017-01-20 | 2018-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法 |
| CN111205290B (zh) * | 2018-11-22 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的结晶形式及其制备方法 |
| WO2022027041A1 (en) | 2020-07-28 | 2022-02-03 | Arcutis Biotherapeutics, Inc. | Topical formulation containing jak inhibitor and laureth-4 |
| KR20230144002A (ko) | 2020-11-17 | 2023-10-13 | 아큐티스 바이오테라퓨틱스, 인크. | 심부 진피 약물 전달을 위한 조성물 및 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100351253C (zh) * | 2000-06-26 | 2007-11-28 | 辉瑞产品公司 | 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物 |
| WO2004087142A1 (en) * | 2003-04-04 | 2004-10-14 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
| AU2006221065A1 (en) * | 2005-02-03 | 2006-09-14 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrimidines useful as inhibitors of protein kinase |
| JP5786257B2 (ja) * | 2011-06-16 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の選択的ｃｃｒ２拮抗薬 |
| JP6075736B2 (ja) * | 2011-12-21 | 2017-02-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途 |
| WO2014194741A1 (zh) * | 2013-06-07 | 2014-12-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐及其制备方法 |
| CN105566327A (zh) | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
-
2015
- 2015-10-09 PT PT158578443T patent/PT3216790T/pt unknown
- 2015-10-09 CA CA2965716A patent/CA2965716C/en active Active
- 2015-10-09 ES ES15857844T patent/ES2754548T3/es active Active
- 2015-10-09 CN CN201580008169.4A patent/CN105980390B/zh active Active
- 2015-10-09 HU HUE15857844A patent/HUE047404T2/hu unknown
- 2015-10-09 DK DK15857844T patent/DK3216790T3/da active
- 2015-10-09 SI SI201530982T patent/SI3216790T1/sl unknown
- 2015-10-09 JP JP2017518183A patent/JP6851572B2/ja active Active
- 2015-10-09 KR KR1020177013839A patent/KR102522895B1/ko active IP Right Grant
- 2015-10-09 US US15/522,991 patent/US10023577B2/en active Active
- 2015-10-09 BR BR112017007953-4A patent/BR112017007953B1/pt active IP Right Grant
- 2015-10-09 EP EP15857844.3A patent/EP3216790B1/en active Active
- 2015-10-09 RU RU2017118193A patent/RU2716260C2/ru active
- 2015-10-09 AU AU2015342444A patent/AU2015342444B2/en active Active
- 2015-10-09 WO PCT/CN2015/091527 patent/WO2016070697A1/zh active Application Filing
- 2015-10-09 PL PL15857844T patent/PL3216790T3/pl unknown
- 2015-10-09 RS RS20191420A patent/RS59669B1/sr unknown
- 2015-10-22 TW TW104134655A patent/TWI672305B/zh active
-
2019
- 2019-11-04 CY CY20191101146T patent/CY1122468T1/el unknown
- 2019-11-08 HR HRP20192030TT patent/HRP20192030T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017007953A2 (pt) | 2017-12-19 |
| US20170313709A1 (en) | 2017-11-02 |
| RU2017118193A3 (hr) | 2019-05-08 |
| ES2754548T3 (es) | 2020-04-20 |
| PL3216790T3 (pl) | 2020-05-18 |
| CN105980390A (zh) | 2016-09-28 |
| PT3216790T (pt) | 2019-11-19 |
| TWI672305B (zh) | 2019-09-21 |
| CY1122468T1 (el) | 2021-01-27 |
| EP3216790A4 (en) | 2018-04-25 |
| CN105980390B (zh) | 2017-07-07 |
| EP3216790A1 (en) | 2017-09-13 |
| BR112017007953B1 (pt) | 2023-12-05 |
| JP6851572B2 (ja) | 2021-03-31 |
| CA2965716A1 (en) | 2016-05-12 |
| RU2716260C2 (ru) | 2020-03-11 |
| EP3216790B1 (en) | 2019-10-02 |
| DK3216790T3 (da) | 2019-11-25 |
| RU2017118193A (ru) | 2018-12-05 |
| RS59669B1 (sr) | 2020-01-31 |
| TW201617347A (zh) | 2016-05-16 |
| WO2016070697A1 (zh) | 2016-05-12 |
| HUE047404T2 (hu) | 2020-04-28 |
| US10023577B2 (en) | 2018-07-17 |
| KR20170078710A (ko) | 2017-07-07 |
| AU2015342444B2 (en) | 2019-12-12 |
| KR102522895B1 (ko) | 2023-04-17 |
| CA2965716C (en) | 2023-03-21 |
| SI3216790T1 (sl) | 2020-02-28 |
| JP2017532327A (ja) | 2017-11-02 |
| AU2015342444A1 (en) | 2017-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192030T1 (hr) | Kristalni oblik bisulfatnog inhibitora jak kinaze i postupak njegovog dobivanja | |
| HRP20200327T1 (hr) | Neurozaštitan sastav koji obuhvaća polygalae, astragali, chuanxiong i angelicu sinensis | |
| EP3597201A3 (en) | Combination therapy for treatment of patients with neurological disorders and cerebral infarction | |
| CN104306532A (zh) | 一种用于治疗下肢静脉曲张的中药 | |
| CN104306531A (zh) | 一种用于治疗血痣的中药 | |
| CN104398915A (zh) | 一种用于慢性湿疹的中药组合物 | |
| CN105617303A (zh) | 一种治疗肺结核的中药 | |
| CN104189727A (zh) | 一种用于治疗经间期情志异常的中药 | |
| CN103565932A (zh) | 治疗风湿的中药 | |
| CN104013937A (zh) | 一种治疗牛流行性感冒的中药 | |
| CN104258326A (zh) | 一种用于治疗肩周炎的中药 | |
| CN102000249B (zh) | 一种治疗手足癣的药物 | |
| CN106138559A (zh) | 一种治疗干癣的组合物中药 | |
| CN104383456A (zh) | 一种用于治疗肋软骨炎的中药组合物 | |
| CN106539914A (zh) | 一种治疗脑动脉硬化的中药配方 | |
| CN106138579A (zh) | 一种治愈***炎、***增生肥大钙化的中药组合 | |
| CN104258096A (zh) | 一种祛斑中药膏 | |
| CN104189626A (zh) | 一种用于治疗湿疹的中药 | |
| CN103721209A (zh) | 一种治疗湿热内盛之带下病的中药方 | |
| CN106540008A (zh) | 一种治疗视力障碍的中药配方 | |
| CN105535807A (zh) | 一种治疗肺部疾病的中药 | |
| CN104042710A (zh) | 一种治疗脑血栓综合症的组合物中药 | |
| CN105943721A (zh) | 一种治疗风寒性感冒的中药胶囊 | |
| CN105560496A (zh) | 一种***的中药 | |
| CN106540033A (zh) | 一种治疗气滞血瘀症的中药配方 |